COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01938456
Recruitment Status : Withdrawn (This study was Cancelled Before Active)
First Posted : September 10, 2013
Last Update Posted : July 28, 2014
Information provided by (Responsible Party):

Brief Summary:
The primary purpose of this study is to evaluate the safety and tolerability of the combination therapy of trametinib and docetaxel with growth factor support in Japanese subjects with Stage IV or a postoperative recurrence non-small cell lung cancer (NSCLC). This study data will be used for making decision for further Japanese development plan for NSCLC. Six evaluable subjects will be enrolled in a dose level to evaluate the safety and tolerability of the combination treatment. Dose-limiting toxicity will be assessed during the first 21 days of combination therapy.

Condition or disease Intervention/treatment Phase
Lung Cancer, Non-Small Cell Drug: Trametinib Drug: Docetaxel Drug: Filgrastim Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
Study Start Date : October 2013
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Trametinib + Docetaxel + Filgrastim
Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
Drug: Trametinib
Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg

Drug: Docetaxel
Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion

Drug: Filgrastim
Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body

Primary Outcome Measures :
  1. Change from baseline in laboratory parameter values. [ Time Frame: Baseline and up to 6 months ]
    Laboratory parameters include: hematology, clinical chemistry, coagulation tests and urinalysis tests.

  2. Change from baseline in vital sign values [ Time Frame: Baseline and up to 6 months ]
    Vital sing measurement include: temperature, systolic blood pressure, diastolic blood pressure, heart rate, and blood oxygen saturation (SpO2)

  3. Number of participants with Adverse events (AEs). [ Time Frame: Baseline and up to 6 months ]
    AEs will be collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice

Secondary Outcome Measures :
  1. Composite of pharmacokinetic (PK) parameters for [ Time Frame: PK samples will be collected at pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 24 hours (pre-dose) post-dose/infusion start ]
    PK parameters include: area under the concentration time curve over dosing interval (AUC[0 to tau]), maximum observed concentration (Cmax), time of occurence of Cmax (tmax), and pre-dose (trough) concentration at the end of the dosing interval

  2. Composite of PK parameters for Docetaxel [ Time Frame: PK samples will be collected at pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 24 hours (pre-dose) post-dose/infusion start ]
    PK parameters include: area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0 to infinite]), area under the concentration time curve from time zero to last quantifiable concentration within subject across all treatments (AUC[0 to t]), Cmax, tmax, systemic clearance of parent drug (CL), and volume of distribution (V)

  3. Tumor response as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 [ Time Frame: 6 months ]
    As per RECIST v1.1 the response will be assessed from target lesion as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), not applicable (NA) or not evaluable (NE) and from non-target lesion as CR, Non-CR/Non-PD, NA or NE

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Subjects eligible for enrolment in the study must meet all of the following criteria:

  • Provided signed written informed consent.
  • 20 years old or older (at the time consent is obtained).
  • Histologically or cytologically confirmed NSCLC.
  • Diagnosed of Stage IV, or postoperative recurrence.
  • Tumor progression after receiving one prior platinum-based chemotherapy. Targeted therapies (gefitinib, crizotinib, etc) with no significant hematological toxicities will not be counted.
  • Performance status score of ≤1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  • All prior treatment-related toxicities must be CTCAE v4.0 <=Grade 1 (except alopecia) at the time of enrollment.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study treatment and agree to use effective contraception throughout the treatment period, and for 4 months after the last dose of study treatment.
  • Men must agree to use effective contraception throughout the treatment period of docetaxel.
  • Adequate organ baseline function defined as Hematology: absolute neutrophil count>=1.5 x 10^9/Liter (L), hemoglobine>=9 gramms/decilitre, platelet>==100 x 10^9/L, Prothrombine time/international normalized ratio and activated partial thromboplastine time<=1.5 x upper limit of normal (ULN) Hepatic: albumin>=2.5 grams/decilitre, total bilirubine <=ULN, aspartate aminotransferase and alanine aminotransferase <=1.5 x ULN if alkaline phosphatase is >=ULN or <=2.5 ULN if alkaline phosphatase is <ULN.

Renal: creatinine<=1.5 x ULN or calculated creatinine clearance >=50 millilter (mL)/minute.

Cardiac:left ventricular ejector factor>=lower limit of normal by echocardiogram.

  • Negative for Hepatitis B surface (HBs) antigen, Hepatitis virus B core (HBc) antibody, HBs antibody and Hepatitis C Virus (HCV) antibody. If HBs antigen is negative and both or either of HBc and HBs antibody is positive, Hepatitis B Virus (HBV) DNA should be measured.

Exclusion Criteria

  • Anti-cancer therapy (including chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, major surgery, tumor embolization or investigational therapy) within the last three weeks, with the following exceptions: six weeks for prior nitrosourea or mitomycin C and two weeks for anti-cancer therapy given continuously or on a weekly basis with limited potential for delayed toxicity.
  • Previously treated with docetaxel
  • Previously treated with MEK inhibitor
  • Current use of a prohibited medication
  • Suspected of or currently have clinically significant infectious disease.
  • Hypersensitivity to polysorbate 80.
  • Hypersensitivity to filgrastim or growth factor
  • History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):

History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes) Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR such as: Evidence of new optic disc cupping, Evidence of new visual field defects on automated perimetry, Intraocular pressure >21 millimeter of mercury (mmHg) as measured by tonography.

  • Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects who require treatment for these conditions should be excluded.
  • History of another malignancy. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or in situ carcinoma are eligible.
  • Any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
  • History of interstitial lung disease or pneumonitis
  • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, metabolic, or cardiac disease).
  • History or evidence of cardiovascular risk including any of the following:

LVEF<LLN A QT interval corrected for heart rate using the Bazett's formula >=480 millisecond.

History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to study treatment are eligible. Currently treated subject should be excluded.

History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to randomization.

Subjects currently treated with anticoagulant. History or evidence of current >= Class II congestive heart failure as defined by New York Heart Association.

Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy.

Subjects with intra-cardiac defibrillators or permanent pacemakers. Known cardiac metastases.

  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO).
  • Lactating female
  • Known Human Immunodeficiency Virus (HIV) infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01938456

Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT01938456    
Other Study ID Numbers: 117132
First Posted: September 10, 2013    Key Record Dates
Last Update Posted: July 28, 2014
Last Verified: July 2014
Keywords provided by GlaxoSmithKline:
Non-small cell lung cancer
GSK1120212 (trametinib)
Phase Ib
combination therapy
MEK inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors